Member Info for VanVan

Words from the Co RNS

It is not anticipated that the potential transaction would constitute a reverse takeover for the purpose of the AIM Rules for Companies.

Why do you keep calling it an RTO. This is misleading and would suggest the shares have to be suspended I believe.

Excuse me for asking but I get the impression that Scancell is what I would term a “conviction” holding for many. Is that correct? Is it the largest holding for a number of you? Is that because you see the potential for multi bagger upside and manageable risk now we are at the Phase111 stage? Just interested. My holding has been growing although I started investing probably nearly 10 years ago!!

The company does not expect that the potential transaction would constitute a reverse takeover under London AIM market rules.

This isn’t a reverse takeover as Scancell are the bigger player. Probably 3 or 4 times bigger than NT

This was the X tweet yesterday you asked to see.

@MarkKleinmanSky - Sky News City editor, City AM columnist

Revealed: Scancell Holdings, a London-listed biotech group with a market capitalisation, is in talks to raise tens of millions of pounds in debt and equity as part of a plan for it to combine with Neuphoria Therapeutics, a small US-listed business. Scancell did not respond.

If they have the results (market sensitive information) are they allowed to hold it back? I agree they should for the reasons in my "Ideal Scenario", but just wondering if this is possible.

Is this the ideal scenario for shareholders:-

1. Complete merger & obtain NasDaq listing

2. Report exceptional clinical data from iSCIB1+ and perhaps from the other 2 arms - Modi1 & GlynMab

3. Receive MHRA approval

4. Attract one or more large US Healthcare Investors and or other Institutional Investors.

5. Secure a partnership with a major pharmaceutical Co, that pays an upfront sum & contributes significantly to Phase 111 Trial costs.

6. Raise from existing retail investors for any funds still required hopefully at a much higher valuation, thereby limiting as much as possible any dilution.

Looks feasible to me and if this plays out I see the share price continuing its strong upward march over the next 6 months.

Please challenge or suggest alternatives.

I guess Scancell will need to raise circa US$100m to cover the cost of the Phase 111 trial. About 500 patients across US, UK & Europe. isn't cheap.

Hopefully it will still be with a pharmaceutical partner(s) who cough up a significant proportion in exchange for commercial rights. Let's hope the forthcoming data results will make this part of the process much easier and enable Scancell to secure very favourable terms, keeping a dilution to a minimum.

Hopefully they will also grab some of the Neuphoria cash balance to help fund it.

A.I. suggests that whilst Scancell is currently valued at £190m, after outstanding data it might be worth 3 times that much! Say raising £80m at a £500m valuation would mean issuing fewer shares, so let's hope they release the data carefully to maximise the Market Cap before we raise the funds say later this year. Do you think that scenario is feasible?

I'm sure that is Phil's objective - only raise the capital after they have generated the strongest possible clinical evidence. Can they delay the results to ease and maximise this process?

As I understand with some input from A.I.: Neuphoria has an experienced biotech Mgmt. who have experience raising capital in the US markets, & understand NasDaq requirements. Obviously they were successful getting their lead programme (drug) to Phase 111 (no mean achievement) but that then failed in late 2025 to meet primary & secondary endpoints. Whilst this isn't uncommon, it means they experienced a major setback and failed to create shareholder value. This obviously reflects badly on the Co.and is why the Co. has much reduced value.

There are a couple of other early stage assets, but nothing to speak off.

But Scancell's reason for interest must primarily be the NasDaq listing, but also an established SEC reporting structure, US Institutional Investor relationships, Cash balance and a US experienced Biotech Board.

As we know a successful US listed Scancell is much more likely to attract specialist US healthcare funds.

As I understand the remaining two assets in the Neuphoria box are:-

1. Mk-1167 (Alzheimer) being developed by Merck & Co, who are funding it, under licence from Euphoria. Entered Phase11 clinical trials in 2025 which triggered a US$15m milestone payment to Neuphoria.

2. BNC 101 - Oncology Cancer programme. This has been licensed to Carina Biotech. It is at an earlier stage than Mk-1167.Development costs largely borne by Carina.

It is a potentially more attractive merger than a simple shell Co. as it has NasDaq listing, circa US$20m of cash, modest ongoing cash burn (funds to end 2027), & 2 partnered programmes that could generate further milestone income without the need for major capital investment.

Obviously the maths is going to be key. What percentage of the combined Co. will Neuphoria shareholders receive etc?

I agree with this summary from greenshaw:- "In my opinion a partnership or sale gives you a quick buck, a move to Nasdaq and a raise to self fund give you a slower riskier route to a much bigger return."

But what interests me is the timing. Given there is so much value accretive news to flow over the short term like a) MHRA clearance for Phase 111 - b) additional iSCIB1 - PFS data and early OS data from Phase 11 Scope Study - c) GlynMab news -d) Modi1 early validation data etc., when would you ideally want to release these results, post or pre such a Funding/Listing type event?

As far as I can see no-one has mentioned all this imminent news in respect of this potential event. If you wanted to keep the door open for a suitor, wouldn't you want to get these releases out into the open first to protect shareholder interests & realise maximum value? But if you are determined to take the longer route to self funding, aided by a NASDAQ listing perhaps you would prefer to keep this "value" creating cards close to your chest. Any thoughts?

I believe we have a Trading Update on 16th July. I'm sure Phase 11 at Nanuloq is doing well with recovery rates picking up towards the yr end target of 90%. I suspect the move to the Main Market has been delayed and will now be Sept/Oct. The MRE5 for Nanuloq must be very close and work starts this week on Black Angel. It seems the SP has a defined pattern. Lot at the 3 year chart. That suggests H2 should see a nice upward trend towards a new high. Fingers crossed

Well the deadline of 1st July fast approaches. Is this going to be extended yet again? I believe the Co. will also give an update on Friday 3rd June, so a big week for Capricorn.

There are more than one way to skin a cat as they say. If this comes off, and I think it will, I think we can be very grateful we now have the likes of Phil leading the ship. The value of business acumen, market knowledge and thinking outside the box all coming into play to maximise our undoubted World Class opportunities.

This is a nice move - a fast track to NASDAQ. I hope they continue to keep their dual listing as some Brokers in the UK don't allow trades on NasDaq I believe. I know that is so backwood & luddite, but I think it's true.

Well done Phil. Looking forward to see how this plays out!

Scancell - Callum Scott - Senior VP Development on Conference panel at 4pm on 1st July. Don’t have any more details.

Thanks for all the efforts and time expended on the BB by so many enthusiastic posters. Always something interesting to read before we receive the real thing.

Worth a listen in my opinion - relevant to gold.

Https://www.youtube.com/watch?v=JYkeP0S_cXQ

Not allowing me to enter the live meeting stating at 1oclock. Are others having the same problem?

Not very professional.

Earlier this morning it said the link wasn't safe & their Certificate wasn't up to date. Now just says Safari unable to open link!

What is the rationale for not confirming GEN1079 is SC129?

According to my A.I. query, if Scancell gets this year + the following we could be looking at a valuation of £500m -£800m

1. iSCIB1+ successfully enters & progresses through Phase111

2. Modi-1 produces convincing Phase 11 data

3. GEN1079 /SC129 advances through early clinical trials with Genmab.

Perhaps it is fairer to say 2027.

On top of this is the potential NasDaq listing, & very short term the MHRA regulatory approval.

Well if that doesn't make you excited, I don't know what will.

Do you long term, highly knowledgeable investors in Scancell think this is feasible or is it A.I. rubbish?

If you are saying GEN1079 is SC129, does this mean mean a significant de-risking moment.? Are you saying it is likely that SC129 is about to go into human studies. I assume this would trigger a nice milestone payment. I believe GEN1079 have disclosed that an IND has been submitted being the regulatory step before human trials.

So we would be looking out for FDA clearance

I believe Genmab is one of the world's leading antibody companies so any solid developments must be another massive endorsement of Scancell & its science.

With two highly credible fronts one can see why large Pharmaceutical companies will be taking great interest in proceedings.

Are we currently mainly valued on iSCIB1+ with the rest of our pipeline projects like the above , largely discounted?

iSCIB1+ - FDA Fast Track approval - Phase 111 programme to start soon - Funding or Partnering news awaited

Modi-1 - Phase 11 data ongoing - undervalued?

GlyNab / Genmab deals - licensed 2 Glymab antibodies to GenMab (one of most respected antibody developers in the industry.) Is GEN1079 actually SC129 ?

Cash & other assets

Three shots at goal or three legs to the stool.

Currently valued at 37p as basically a melanoma story when actually it is so much more - Plus an Antibody platform story.

So much upside to come in my opinion but DYOR.

My post said I should read your posts but I didn't say whose those where!! Sorry I missed out "Redeyemines". Hope it now makes more sense and perhaps Redeyemines will provide his latest overview on how matters might be progressing. I really can't understand given all the things that have been going on, why Fanning can't update shareholders. Poor show in my opinion.